

Treatment Options for Differentiated Thyroid Carcinoma

Joachim Feldkamp*

Department of Endocrinology and Diabetes, Bielefeld University, Bielefeld, Germany

Abstract

There are various definitions of the term in the literature: Thyroid Carcinoma Occult". According to the most recent online version of the Merriam-Webster dictionary, "occult carcinoma" means "not manifest or detectable by clinical methods alone" as well as "not present in macroscopic amounts." The phrase "occult primary malignancy" is defined as "unknown primary malignancy that is symptomless, which first manifests itself as metastases or secondary paraneoplastic phenomena" in the 2002 edition of the McGraw-Hill Concise Dictionary of Modern Medicine.

Keywords: Anaplastic • Carcinoma • Macropod

Introduction

"Occult thyroid carcinoma" was defined by Moosa and Mazzaferri in 1997 as "impalpable thyroid carcinoma that is generally smaller than 1.0 cm." Stedman's Medical Dictionary (2006) uses a more precise definition of size, defining "occult papillary carcinoma of the thyroid" as "microcarcinoma of the thyroid" or "microscopic papillary carcinoma of the thyroid" that is typically well encapsulated and less than 5 mm in diameter. Papillary thyroid microcarcinoma (PTMC) is defined as "papillary carcinoma measuring 1.0 cm or less in maximal diameter while other clinico-pathological features, such as metastasis to regional lymph nodes and/or distant organs as well as extrathyroid extension are not considered" in the WHO (World Health Organization) classification system. Shaha uses a more expansive definition of PTMC: In the past, a microcarcinoma was thought to be less than 1.5 cm [1,2].

Discussion

The entire mass was found and removed. A histological examination revealed that the tumor cells invaded the fibrous stroma by forming papillary and glandular structures. The tumor cells were cubic or columnar and had crowded, overlapping nuclei that gave the appearance of ground glass. A few thyroid follicular cells surrounded the nuclear grooves, which were clearly visible. Cytoplasmic triacylglycerol and nuclear thyroid transcription factor 1 were both stained by immunohistochemistry. A papillary thyroid carcinoma was suggested by the pathological findings. The mass was identified as accessory thyroid papillary carcinoma based on both clinical and imaging findings.

In addition, the presence of the follicular variant of papillary thyroid cancer and other risk factors, such as extrathyroid invasion, would necessitate more aggressive treatment and extended follow-up than would be the case for patients older than 16 years. In patients with papillary thyroid carcinoma (PTC), central lymph node metastases (CLNM) are thought to be a predictor of local recurrence; however, the significance of prophylactic central lymph node dissection is debatable. Zeng and co. studied 1,054 consecutive PTC

patients with the intention of developing a nomogram for individualized clinical decisions and determining the clinical factors associated with CLNM. $p=0.043$, CLNM was found in 31.4 percent (168/535) of non-Hashimoto's thyroiditis (HT) patients and 39.2 percent (83/212) of HT patients.

Papillary and follicular thyroid carcinomas account for the majority of the tumors, followed by anaplastic and non-follicular medullary thyroid carcinomas. The clinical spectrum encompasses a wide range of conditions, from papillary microcarcinomas, which are frequently found in the elderly and are often almost unnoticeable, to rare cases of anaplastic thyroid carcinomas and primary squamous cell carcinoma of the thyroid, both of which have unfavorable outcomes.

Clinical follow-up of a Danish RET Leu56Met cohort investigated the significance of the Leu56Met variant in the RET gene. None of the patients met the predetermined criteria for MEN. The Leu56Met variant suggests that it is a common variant without pathogenic significance in the population, with an allele frequency of 0.59 percent. It was a zoo animal that was fed commercial macropod pellets, poultry pellets, lucerne hay and vegetables (sweet potato and carrot) in an outdoor enclosure with another wallaby. A 6-month history of swelling on the left side of the neck was presented to the wallaby. The animal had been difficult to handle on a regular basis, so the owners weren't sure if the swelling existed until it got big enough to be seen by looking at it from a distance.

To be considered an enlarged lymph node, it was deemed to be too caudal. Dental or mandibular disease was not present. The mass was examined by ultrasound after the patient was anesthetized with isoflurane during mask induction and maintenance. The mass did not contain the jugular veins. The mass was close to the common carotid artery, which had a distinct wall from the mass. Neither vascular invasion nor the formation of a thrombus were evident. The thyroid on the opposite side was not found. In the past, the term "variant" has been used in thyroid pathology to describe the histologic subtype of a particular type of tumor. Examples include the tall cell variant, columnar variant, hobnail variant, clear cell variant and papillary variant of papillary thyroid carcinoma (PTC), among others.

To avoid confusion with genetic variants and to standardize terminology across all volumes of the WHO classification's fifth edition, the new classification uses the term "subtype" rather than "variant." As a result, "histologic subtype" ought to take the place of "histologic variant." The genetic variant should be given priority when the WHO classification only uses the term "variant." The "molecular sponge" function or ceRNA role of some circRNAs is the subject of the majority of current research. Artificial circRNAs can be engineered in a variety of ways to serve as promising therapeutic molecular tools, according to ceRNA theory. In this field, which is notable demonstrates that cell autophagy is influenced by circEIF6's association with chemo-resistance (cisplatin-resistance). More importantly, circRNAs can be secreted into blood, saliva and even exosomes, which play important roles in the tumor microenvironment. This suggests that the

*Address for Correspondence: Joachim Feldkamp, Department of Endocrinology and Diabetes, Bielefeld University, Bielefeld, Germany; E-mail: feldkamp00@gmail.com

Copyright: © 2022 Feldkamp J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 28 August, 2022, Manuscript No. rtr-23-86842; **Editor assigned:** 30 August, 2022, PreQC No. P-86842; **Reviewed:** 15 September, 2022, QC No. Q-86842; **Revised:** 21 September, 2022, Manuscript No. R-86842; **Published:** 29 September, 2022, DOI: 10.37421/2684-4273.2022.6.27

level of circRNAs in body fluids and FNAB samples could help with clinical management. Some examples of these circRNAs include circ_0006156, circ_MAN1A2 and circ_RASSF2.

Radiofrequency ablation (RFA) appears to be the most effective energy currently used to treat differentiated thyroid carcinoma, raising the question of thermal energies. The indications for RFA in thyroid malignancy are in T1a and T1b tumors without high risk factors, particularly in patients who are poor surgical candidates, refuse surgery, or have a recurrent lesion in cases where previous surgery or radioiodine treatment make a rescue surgery technically hazardous and with the potential to decrease the patient's quality of life. Although RFA is currently used primarily in patients with benign nodules, its indications in thyroid malignancy are in T1a and T1b. Recent metaanalyses indicate that the rates of complications in malignancies are major (5.5%) and minor (10%), with recurrent lesions having slightly higher rates (10% and 15%, respectively). The use of these methods in thyroid carcinoma calls for prospective, well-designed clinical trials [3-5].

Conclusion

In the absence of symptoms, the patient, a 45-year-old woman, underwent an investigation for other diseases and had a neck ultrasound, which coincidentally revealed the presence of thyroid micronodules. Thyroid prevailing nodule (middle third of right lobe).

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Curiel, Tyler J., Pui Cheng, Peter Mottram and Xavier Alvarez, et al. "Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer." *Cancer Research* 64 (2004): 5535-5538.
2. Gordon-Alonso, Monica, Thibault Hirsch, Claude Wildmann and Pierre van der Bruggen, et al. "Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration." *Nature Communications* 8 (2017): 1-15.
3. Marie, Caroline, Nicolas A. Giraldo, Hélène Kaplon and Claire Germain, et al. "Tertiary lymphoid structures, drivers of the anti tumor responses in human cancers." *Immunological Reviews* 271 (2016): 260-275.
4. Li, Taiwen, Jingyu Fan, Binbin Wang and Nicole Traugh, et al. "TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells." *Cancer Research* 77 (2017): e108-e110.
5. Ali, H. Raza, Leon Chlon, Paul DP Pharoah and Florian Markowitz, et al. "Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study." *PLoS Medicine* 13 (2016): e1002194.

How to cite this article: Feldkamp, Joachim. "Treatment Options for Differentiated Thyroid Carcinoma." *Rep Thyroid Res* 06 (2022): 27.